The common HER2 mutation, HER2 Y772_A775dup / A775_G776insYVMA, was identified to confer increased resistance to afatinib and chemotherapy treatments in patients with NSCLC [47–49]. Here, ERBB2 is linked to non-small cell lung carcinoma.